Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.2% - Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price traded down 7.2% on Tuesday . The company traded as low as $0.28 and last traded at $0.29. 30,458,623 shares were traded during mid-day trading, a decline of 56% from the average session volume of 68,841,906 shares. The stock had previously closed at $0.31.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a report on Wednesday, January 1st. They issued a "hold" rating on the stock.

Tonix Pharmaceuticals Stock Down 7.8 %

The stock has a market cap of $53.84 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock has a fifty day moving average of $0.24 and a two-hundred day moving average of $0.34.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analysts' expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.